For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The Lancet ...
Mar 13, 2023
0
6
For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and ...
Feb 10, 2023
0
2
Underweight and severe obesity are associated with decreased survival in patients with multiple myeloma (MM), according to a study published online Jan. 12 in the Blood Cancer Journal.
Jan 23, 2023
0
14
Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology (VHIO), presented data from the international phase III SUNLIGHT study during an Oral Abstract Session at this week's American Society of Clinical Oncology's ...
Jan 23, 2023
0
8
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit ...
Jan 20, 2023
0
4
A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma. The study is believed to be the first metastatic pancreatic ...
Jan 20, 2023
0
5
For patients with newly diagnosed multiple myeloma (MM), mass spectrometry (MS) can monitor treatment response, according to a study published online Jan. 4 in Blood Cancer Journal.
Jan 19, 2023
0
18
Researchers from the University of Chicago Medicine Comprehensive Cancer Center and colleagues in Poland report promising results from their ongoing ATLAS trial, published on January 12, 2023 in the journal Lancet Oncology.
Jan 13, 2023
0
25
The transition of a low-grade, slow growing brain tumor to a lethal one can be delayed if neurosurgeons remove as much as possible soon after diagnosis, according to the results of a study led by UC San Francisco.
Jan 4, 2023
0
23
Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study published ...
Jan 3, 2023
0
7
